Pipeline

RBD4059, a GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM, is being developed for treatment of thrombotic diseases. As the world's first and most advanced siRNA drug in clinical development targeting FXI (First-In-Modality), RBD4059 offers distinct advantages over both small molecules and antibodies for FXI inhibition with the extended dosing intervals up to several months as well as the reduced risk of immune reactions and anti-drug antibodies (ADA). Furthermore, RBD4059 combines the advantages of FXI-targeting with siRNA drug technology, offering reduced bleeding risk while maintaining strong efficacy compared to standard-of-care. The Phase IIa clinical trial of RBD4059 has been completed in Europe. The research results demonstrate high potency, long-lasting with excellent safety profile. The two Phase IIb clinical trial applications to EMA respectively for the treatment of SPAF and VTE had been submitted in April and May 2026.

RBD7022, a GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM, is being developed for the treatment of hyperlipidemia. By inhibiting the expression of PCSK9, RBD7022 reduces blood LDL-C levels. The Phase I and Phase II clinical trials of RBD7022 have been completed in China, and Phase III clinical trial has been launched in 2026. Development, manufacture and commercialization rights for RBD7022 in Mainland China, HK, and Macau have been licensed to Qilu Pharmaceutical.

RBD5044, a GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM, is being developed for the treatment of triglycerides (TGs)-type hypertriglyceridemia. RBD5044 is the second siRNA globally to enter clinical development targeting ApoC3, existing clinical results demonstrated a favorable safety profile, along with robust and long-acting therapeutic effects. These results support sustained TG control with quarterly or bi-annual dosing schedules, significantly improving patient adherence. The MRCT Phase II clinical trials of RBD5044 are being conducted in Europe and China.